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Abstract
Background: Radiation-induced osteosarcomas are a recognized complication of radiation therapy. Owing to the
fact that it is rare, publications on radiation-induced osteosarcoma of the skull base are limited to a small series and
some case reports.
Case presentation: We describe a rare case of a patient with a skull base radiation-induced osteosarcoma treated
11 years before with ionizing radiation for an undifferentiated carcinoma of the nasopharynx. The patient was
treated with chemotherapy alone, but he died after the third cycle.
Conclusions: Radiation-induced osteosarcoma of the skull base after treatment of nasopharyngeal carcinoma is a
very rare but very aggressive complication with a poor prognosis. Chemotherapy gives bad results, and regular follow-
up of treated patients should be considered.
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Background
Radiation-induced osteosarcomas are rare clinical entities
that are recognized as a complication of radiation therapy
and are associated with a poor prognosis. Their incidence
ranges from 0.01 % to 0.03 % of all irradiated patients
[1, 2] and 5.5 % of all osteosarcomas [2]. This incidence
could increase in the future because radiation therapy
has become more common and developed, and patient
survival has improved. Reports of radiation-induced
osteosarcoma of the skull base are limited to a small
series and some case reports. In this report, we describe
a very rare case of skull base radiation-induced osteo-
sarcoma in a patient treated with ionizing radiation for
undifferentiated carcinoma of the nasopharynx.
Case presentation
A 29-year-old Moroccan man presented to our hospital
with a 6-month history of headache in his left skull,
associated with homolateral facial pain, numbness, dip-
lopia, exophthalmia, eye watering, and an episode of epi-
staxis. Eleven years before, he had received radiotherapy
for undifferentiated carcinoma of the nasopharynx, ini-
tially classified as T1N1M0. The radiation dose he had
received was 70 Gy in 35 fractions delivered using the
classic 3-fields technique (2 lateral opposed fields abut-
ted to an anterior low-neck field). This technique had
been applied during the previous 20 years because it
seemed to be the simplest.
The patient’s physical examination revealed a left ptosis,
hemifacial edema, and decreased visual acuity. Magnetic
resonance imaging disclosed a tumor process of the skull
base involving the sphenoid bone with its two left wings,
the squamous part of the left temporal bone, and the left
maxillary bone, associated with intracranial expansion, as
well as a second, isolated mass in the temporal lobe
(Fig. 1).
Direct nasofibroscopy with biopsy was performed. The
histological results with immunohistochemistry were in
favor of osteosarcoma with the following characteristics:
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spindle-cell neoplasm pleomorphism with badly limited
cytoplasm, an irregular nucleus with frequent atypical mi-
toses, and an associated osteoid matrix. The results of im-
munohistochemistry with anti-AE1/AE3, anti-endomysial
antibodies, and anti-CD34/CD31 were negative (Fig. 2).
A complete search for distant metastasis by positron
emission tomography and by enhanced computed tom-
ography of the chest, abdomen, and pelvis produced no
results. We reviewed the initial pathology and docu-
mentation outlining the patient’s original radiation ther-
apy and confirmed that the tumor developed in the
previously irradiated field. The tumor was deemed unre-
sectable, and further radiation therapy was not advised.
The patient was started on chemotherapy consisting of
four cycles of ifosfamide, cisplatin, and doxorubicin, to
be followed by four planned cycles of doxorubicin and
ifosfamide. A physical evaluation after the second cycle re-
vealed improvement of clinical signs, but after this initial
remission, the patient’s condition deteriorated, and he died
1 month after his third cycle of chemotherapy.
Discussion
Radiation therapy for head and neck cancer is a well-
accepted modality of treatment. It is a standard treat-
ment for carcinoma of the nasopharynx. However, as
with all treatment modalities, there are short- and long-
term morbidities and occasionally mortalities. One of
the most dreaded complications of radiation therapy is
the formation of new malignancies. Although difficult
to estimate, the incidence of radiation-induced tumors is
extremely low [3]. The most frequent radiation-induced
tumors are fibrosarcoma and osteosarcoma. Sarcomatous
Fig. 1 Magnetic resonance imaging studies show a tumor process of the skull base involving the sphenoid bone with its two left wings, the
squamous part of the left temporal bone, associated with intracranial expansion, as well as a second, isolated mass in the temporal lobe. a T1-weighted,
gadolinium-enhanced axial magnetic resonance imaging scans. b T1-weighted, axial magnetic resonance imaging scans. c T2-weighted axial magnetic
resonance imaging scans
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tumors account for most radiation-induced neoplasms in-
volving the head and neck, and most occur in the facial
skeleton. Very few involve the skull base [4–7]. Postirradi-
ation osteosarcomas are rare, accounting for 3–6 % of all
cases of osteosarcoma and 0.01–0.03 % of all irradiated
patients [1, 2]. The incidence of radiation-induced tumors
is increasing in the oncology population as a result of
increased survival through the development of cancer
treatment [8]. Cahan et al. described the following criteria
for radiation-induced sarcoma: (1) The initial and second-
ary neoplasms are of significantly different histological
types; (2) the secondary neoplasm must arise within the ir-
radiated area; (3) there must be a long latency period after
radiation (>5 years); and (4) all sarcomas must be proven
histologically [9]. Our patient fulfilled all these conditions,
and the diagnosis of radiation-induced osteosarcoma was
thus established.
The pathogenesis of postirradiation sarcoma is un-
known. Various predisposing factors have been suggested:
radiation dose, age of the patient at radiation exposure, as-
sociation with chemotherapy, and genetic predisposition
[10]. Documentation of new mutations in genes impli-
cated in malignant transformation after radiation therapy,
such as the p53 and retinoblastoma tumor suppressor
genes, further supports induction of malignancy [11], sug-
gesting that loss of these tumor suppressor genes plays a
role in the development of these lesions [12, 13]. Friend et
al. proposed a link between retinoblastomas and osteosar-
comas [14], and Patel et al. reported 2 of 16 patients who
had retinoblastoma as the original lesion, for which the
patients received radiation [15].
The latency period specified by Cahan et al. is more
than 5 years. Since publication of their report, there have
been some reports of patients developing radiation-
induced sarcomas with shorter latency periods (as short
as 2 years) [15–18]. Laskin et al. [19] reported a link be-
tween shorter latency periods and worse outcomes with
radiation-induced soft tissue sarcomas, but this relation-
ship has not been further substantiated in the literature.
Patel et al. did not find any significant correlation be-
tween latency period and survival [15]. It is believed that
the mean latency is inversely proportional to the dose
received in radiotherapy. However, some authors indi-
cate that the inverse relationship between dose and la-
tency applies only to very high doses [20–22]. Other
authors have noted that the latency period ranged from
3.5 to 33 years (median 10 years) [23]. In our patient,
the tumor appeared 11 years after radiation.
Our review of skull base radiation-induced osteosar-
coma cases revealed that the most common primary
tumor for which radiation was initially received is pituit-
ary adenoma. We found no case of radiation-induced
osteosarcoma in skull base after radiotherapy for naso-
pharyngeal carcinoma. Otherwise, the anatomic site of
the sarcoma has important implications for treatment
and outcome. Reports detailing radiation-induced sar-
coma in patients who were treated for head and neck
cancer, particularly for nasopharyngeal carcinoma, are
relatively few and limited to case reports and a few small
case series [6, 24, 25].
Mian et al. reported a series of 53 patients who devel-
oped radiation-induced malignancies after radiotherapy
for nasopharyngeal carcinoma between 1964 and 2003.
Fibrosarcoma was the most frequent histologic type at
41.5 % (22 cases), followed by osteosarcoma at 22.6 %
(12 cases), without any being located in the skull base
[25]. Malone et al. reported 35 cases of second malignant
tumors after treatment of nasopharyngeal carcinoma. Ten
cases of osteosarcoma were found, also without any
located in the skull base [26]. Radiation-induced sarcoma
in patients who were treated for head and neck cancer
most often occurs in the facial skeleton; very few involve
the skull base [5, 11, 25–27].
Complete surgical excision is the treatment of choice
for radiation-induced osteosarcoma, although this can be
Fig. 2 a and b High-grade osteosarcoma with spindle-cell pleomorphic
neoplasm, badly limited cytoplasm, and osteoid matrix. Original
magnification × 20 (a) and × 40 (b)
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Table 1 Characteristics of various published cases of skull base radiation-induced osteosarcoma






Site of radiation-induced osteosarcoma Treatment Survival period
Amine (1976) [32] 16/F Pituitary adenoma 51.0 10 Sella Radiation 5 weeks
Tanaka (1989) [33] 57/M Craniopharyngioma 110 15 Sphenoid wing Embolization surgery 2 weeks
Salvati (1994) [34] 45/M Pituitary adenoma 44 12 Sphenoid Radiation (50 Gy) 16 months
Gnanalingham (2002) [35] 67/F Pituitary adenoma 52 14 Sella Surgery –
Hansen (2003) [36] 39/M Pituitary adenoma 52 22 Sella, clivus Surgery Short
Bembo (2004) [37] 45 Pituitary adenoma 46 5 Sella Surgery 7 weeks
Patel (2011) [15] 44 Craniopharyngioma 60 9 Sphenoid-ethmoid sinus Chemotherapy 16 months
Yamada (2012) [38] 75/F Pituitary adenoma 50 20 Sphenoid sinus Cyberknife surgery, chemotherapy 24 months
Patel (2011) [15] 54/M Maxillary and adenoid cystic carcinoma 60 12 Sphenoid, frontal and temporal bone Surgery, chemotherapy 13 months
63/M Squamous cell carcinoma, nasal cavity – 4.5 Palate +maxillary sinus Surgery, chemotherapy 47 months
50/M Squamous cell carcinoma, nasal cavity – 14 Infratemporal fossa Surgery, chemotherapy 17 years
44/F Craniopharyngioma – 9 Sphenoidal, ethmoidal bone Chemotherapy 18 months
15/M Retinoblastoma – 15 Zygoma Surgery, chemotherapy 62 months
22/M Retinoblastoma – 20 Ethmoid +maxillary sinus Surgery, chemotherapy –
10/M Rhabdomyosarcoma – 6.75 Mastoid + jugular foramen Surgery, chemotherapy, radiation 29 months
31/M Rhabdomyosarcoma 60 18 Palate + infratemporal fossa Surgery, chemotherapy 143 months
26/M Retinoblastoma 35 25 Surgery, chemotherapy 41 months
Hansen (2003) [36] 29/M Pituitary adenoma 5000 rad 22 Sphenoid, frontal clivus Chemotherapy Very short
Patel (2014) [39] 52/M Craniopharyngioma 50 22 Sella + clivus Surgery 1 month
Our patient 28/M Nasopharynx carcinoma 70 11 Sphenoid + maxillary bone Chemotherapy 6 months











difficult when there is skull base involvement. The
benefit of adjuvant therapy has not been established on
a previously irradiated field [8]. For patients with unre-
sectable tumors, radiotherapy and/or chemotherapy are
acceptable alternatives. Some reports described the ef-
fectiveness of chemotherapy, with variable results, using
doxorubicin, ifosfamide, methotrexate, carboplatin, vin-
cristine, or etoposide [28–30], but a definitive protocol
has not been established.
Radiation-induced osteosarcomas are considered to be
highly aggressive lesions. Local recurrence for primary
osteosarcomas of the head and neck has been reported
to be 22 % [31], and 86 % for radiation-induced osteo-
sarcoma [15].
Patel et al. [15] compared a skull base radiation-
induced osteosarcoma group with a calvarial radiation-
induced osteosarcoma group and found that the median
progression-free survival intervals were 9.5 months and
19 months, respectively (P = 0.6322). These differences
were not statistically significant. The median overall sur-
vival times of patients with radiation-induced osteosar-
coma of the skull base was 41 months (Table 1).
The 5-year disease-free survival time for patients with
radiation-induced osteosarcoma has been reported to be
17 % [10], as opposed to 70 % in patients with primary
osteosarcomas of the head and neck [31].
Conclusions
Radiation-induced osteosarcoma of the skull base after
treatment of nasopharyngeal carcinoma is a very rare
but very aggressive complication with a poor prognosis.
The overall incidence seems quite low and should not
change current practice; however, regular follow-up of
treated patients should be considered. Complete surgical
excision, if possible, can optimize survival of these pa-
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